Catalyst Pharmaceutical Partners Inc. (CPRX)

Trade CPRX now with
8/11/2020 6:17:55 AM Catalyst Pharma: USPTO Issues Notice Of Allowance Of Patent Application For Methods Of Administering 3,4-Diaminopyridine
6/23/2020 8:09:12 AM Catalyst Pharmaceuticals Promotes Jeffrey Del Carmen To Chief Commercial Officer
4/8/2020 6:36:02 AM Catalyst Pharma Provides Update On Impact Of COVID-19 Pandemic On Its Business Activities
1/6/2020 8:12:46 AM Catalyst Pharmaceuticals Expects Firdapse 2019 Net Product Revenues To Be $102 Mln
9/13/2019 6:05:10 AM Catalyst Pharma Determines Not To Proceed With Previously Announced Public Offering Of Common Stock
5/30/2019 8:07:53 AM Catalyst Amends License Agreement For Firdapse To Expand Commercial Territory
1/4/2019 8:05:11 AM Catalyst Announces Publication Of Clinical Data From The Investigator-Sponsored Phase IIb Study Evaluating Firdapse
12/18/2018 12:05:24 PM Catalyst Pharmaceuticals Announces Definitive Agreement With Endo For Vigabatrin Tablets
12/3/2018 8:10:06 AM Catalyst Expects Firdapse U.S. Launch Scheduled For Early In Q1 Of 2019
8/20/2018 8:04:11 AM Catalyst Pharma Appoints Stanley Iyadurai As VP Of Clinical Development
6/13/2018 8:03:28 AM Catalyst Pharmaceuticals Appoints Daniel Brennan As Chief Commercial Officer